课题基金 / 基金详情

IL-32, a new biomarker and potential therapeutic target for chronic inflammation and residual reservoirs in HIV-infected individuals

IL-32, a new biomarker and potential therapeutic target for chronic inflammation and residual reservoirs in HIV-infected individuals
IL-32，一种新的生物标志物和 HIV 感染者慢性炎症和残留储存库的潜在治疗靶点
批准号：
344296
负责人：
Tremblay Ccile L
金额：
$144.25万
依托单位：
Centre hospitalier de l'Universit de Montral (CHUM)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-03-01 至 2021-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=344296&lang=en
关键词：
Biomarker Dysbiosis Hiv Immune Activation Hiv Reservoirs Il-32 Inflammation Microbiota Th17 Lymphocytes Therapeutic Target

项目摘要

项目成果

Tremblay Ccile L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
HIV-infected individuals are aging and present increased risks for age-associated health complications such as cardiovascular diseases (CVD). Inflammation plays a critical role in HIV-associated premature aging phenotypes. HIV infection induces a state of
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COVIH study: COVID-19 burden in HIV infected individuals.
COVID-19 household study to assess secondary attack rates and the proportion asymptomatic, including children
Symposium on HIV and HCV in indigenous people living in Quebec
Determinants of increased risk of cardio-vascular diseases in HIV-infected individuals
海外基金